Xvivo Perfusion ABXVIPF -1.32%91 Equity-to-Asset is 0.88 as of Mar. 2026, which is 1% below its 10-year median of 0.89. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.02 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 89.84% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Xvivo Perfusion AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $232.84 Mil. Xvivo Perfusion AB's Total Assets for the quarter that ended in Mar. 2026 was $264.99 Mil.
Therefore, Xvivo Perfusion AB's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.88.
The historical rank and industry rank for Xvivo Perfusion AB's Equity-to-Asset or its related term are showing as below:
XVIPF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.83 Med: 0.89 Max: 0.95
Current: 0.88
During the past 13 years, the highest Equity to Asset Ratio of Xvivo Perfusion AB was 0.95. The lowest was 0.83. And the median was 0.89.
XVIPF's Equity-to-Asset is ranked better than 89.84% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs XVIPF: 0.88
Xvivo Perfusion AB (OTCPK:XVIPF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Xvivo Perfusion AB Equity-to-Asset Related Terms
Xvivo Perfusion AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XVIPF vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Xvivo Perfusion AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Equity-to-Asset of 0.88 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Xvivo Perfusion AB and its competitors. This is near median its historical median of 0.89. Over the past decade, Xvivo Perfusion AB's Equity-to-Asset has ranged from 0.83 to 0.95. According to the industry distribution chart, Xvivo Perfusion AB ranks #87 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 10.2%.
Is Xvivo Perfusion AB's Equity-to-Asset too high?
Xvivo Perfusion AB's current Equity-to-Asset of 0.88 is near median its 10-year median of 0.89. Over the past 10 years, this metric has ranged from a low of 0.83 to a high of 0.95. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Xvivo Perfusion AB's value of 0.88 is 37.5% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #87 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #87 out of 856 companies for Equity-to-Asset. This places Xvivo Perfusion AB in the top 10% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Xvivo Perfusion AB's value of 0.88 is 37.5% above this benchmark. Historically, Xvivo Perfusion AB's own Equity-to-Asset has ranged from 0.83 to 0.95 over the past decade. While the company's 10-year median is 0.89 vs. the industry median of 0.64, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Equity-to-Asset of 0.88 is 37.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Equity-to-Asset is 0.88, which is near median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.02, compared to a current price of $29.00 — trading 31% below its estimated fair value. The current Equity-to-Asset is 0.88, which is near median its 10-year median of 0.89 and 37.5% above the Medical Devices & Instruments industry median of 0.64. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Equity-to-Asset is 0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31% below its estimated GF Value™ of $42.02.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Equity-to-Asset: 0.88 (near median its 10-year median of 0.89)
GF Value™: $42.02 vs. price of $29.00 (31% below fair value)
Industry Position: 37.5% above the Medical Devices & Instruments median (#87 of 856)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
